On Thursday, Turquoise Hill Resources Ltd (NYSE:TRQ)’s shares declined -1.82% to $29.72.
Turquoise Hill Resources declared the second quarter 2015 production for Oyu Tolgoi.
Concentrate production for Q2’15 raised 64.6% over Q1’15 due to a 20.1% enhance in throughput and higher head grades. Throughput for Q2’15 was the best Oyu Tolgoi has practiced since operations began. Copper and gold in concentrates raised 64.5% and 178.1% respectively over Q1’15.
Oyu Tolgoi began accessing higher-grade material in Q2’15. Production of higher-grade ore is predictable to continue in the second half of 2015. Turquoise Hill continues to expect Oyu Tolgoi to produce 175,000 to 195,000 tonnes of copper and 600,000 to 700,000 ounces of gold in concentrates in 2015.
A planned two-week concentrator shutdown is presently underway at Oyu Tolgoi.
Turquoise Hill Resources Ltd., together with its auxiliaries, operates as a mining company. Its principal material mineral resource property is the Oyu Tolgoi copper-gold mine located in the southern Mongolia. The company was formerly known as Ivanhoe Mines Ltd. and changed its name to Turquoise Hill Resources Ltd. in August 2012.
Royal Dutch Shell plc (ADR) (NYSE:RDS.A)’s shares gained 0.23% to $57.10.
Royal Dutch Shell plc (ADR) (RDS-A) declares that it has issued 23,430,143 A ordinary shares of €0.07 each in relation to the scrip dividend program for the first quarter 2015 interim dividend. In accordance with Rule 2.10 of the City Code on Takeovers and Mergers (the “Code”), Royal Dutch Shell plc confirms that following this issue, it has the following relevant securities held and in issue outside treasury: 3,918,015,024 A ordinary shares of €0.07 each, with ISIN reference GB00B03MLX29; and 2,440,410,614 B ordinary shares of €0.07 each, with ISIN reference GB00B03MM408, each admitted to trading on the main market of the London Stock Exchange and on Euronext Amsterdam. The total number of Royal Dutch Shell plc A ordinary shares and B ordinary shares held and in issue outside treasury is 6,358,425,638. Royal Dutch Shell plc has A and B American Depositary Shares (“ADSs”) listed on the New York Stock Exchange. The Bank of New York Mellon acts as depositary. Each A ADS represents two A ordinary shares of €0.07 each and each B ADS represents two B ordinary shares of €0.07 each. The Royal Dutch Shell plc A ADSs have the trading symbol RDS.A and ISIN US7802592060 and the Royal Dutch Shell plc B ADSs have the trading symbol RDS.B and ISIN US7802591070.
This declarement is not intended to and does not constitute or form part of any offer to sell or subscribe for or any invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction following the Shell-BG combination or otherwise, nor shall there be any sale, issuance or transfer of securities of Shell or BG following the Shell-BG combination in any jurisdiction in contravention of applicable laws.
This declarement does not constitute a prospectus or prospectus equivalent document.
Royal Dutch Shell plc operates as an independent oil and gas company worldwide. It operates through Upstream and Downstream segments. The company explores for and extracts crude oil, natural gas, and natural gas liquids. It also converts natural gas to liquids to provide fuels and other products; markets and trades natural gas; extracts bitumen from mined oil sands and converts it to synthetic crude oil; and generates electricity from wind energy.
At the end of Thursday’s trade, EnteroMedics Inc (NASDAQ:ETRM)‘s shares surged 10.56% to $0.398.
EnteroMedics Inc. (ETRM), a developer and manufacturer of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, recently declared the closing of its formerly declared public offering of 32,000,000 units (the “Offering”) generating net proceeds of about US$14.7 million, with each unit compriseing of one share of common stock and one Series A warrant to purchase one share of common stock at a purchase price of $0.50 per unit. Investors whose purchase of units in the offering would result in them beneficially owning more than the initial beneficial ownership limitation to be comprised of in the warrants following the consummation of the offering will have the opportunity to acquire units with Series C pre-funded warrants substituted for any common stock they would have otherwise attained over the initial beneficial ownership limitation, paying the same price of $0.50 per unit. The Series A warrants will be exercisable right away and will expire 42 months after their date of issuance at an exercise price of $0.60 per share. The pre-funded Series C warrants will be exercisable right away and will expire five years following issuance.
Canaccord Genuity acted as sole book-running manager and Craig-Hallum Capital Group acted as co-manager for the offering. Northland Securities and Roth Capital Partners served as financial advisors to the Company in connection with this transaction.
EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company’s proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. It develops the Maestro Rechargeable System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness.
Chambers Street Properties(NYSE:CSG), ended its Thursday’s trading session with 1.85% gain, and closed at $7.69.
Chambers Street Properties (CSG), a real estate investment trust focused on acquiring, owning and operating net leased industrial and office properties, today announced it has sold a 142,500 square foot office property located at 225 Summit Avenue in Montvale, New Jersey to a subsidiary of Memorial Sloan Kettering Cancer Center for $37.0 million. The sale of this property further reduces the Company’s exposure to the New Jersey office market.
Chambers Street Properties is a equity real estate investment trust. The firm invests in the real estate markets of United States, United Kingdom, and Germany. It focuses on acquiring, owning and operating the properties. The firm invests in industrial and office properties. Chambers Street Properties was founded in 2004, and is based in New Jersey, United States. Chambers Street Properties operates as a partner of CB Richard Ellis Investors, L.L.C.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
